Skip to content

Quick Access

Contact Us

Search

What can we help you find?

Site Navigation

Access FMT
- Clinical
  - Investigational FMT for C. difficile
  - FMT for Clinical Research
- Non-clinical Research
- Investigational FMT Access
- Research
  - Non-Clinical
- Microbiome Conservation
- Biobanking
- Global Health
Join Us
Media

The Risk of Inflammatory Bowel Disease Flares after Fecal Microbiota Transplantation: Systematic Review and Meta-Analysis

Academic Publication

Share

Back To Publications

Academic Publication

Footer

Get Our Emails

Your Name

Your Email (Required) *

Connect with us

Helpful Links

Our Mission and Story

Latest Features

Global Microbiome Conservancy (GMbC)

FMT For Patients

FMT For Clinicians

Get Involved

Let’s Connect

info@openbiome.org

phone: (617) 575-2201
fax: (617) 575-2201

The investigational fecal microbiota transplantation (FMT) treatments discussed on this website and associated OpenBiome materials have been not been approved or licensed by the U.S. Food and Drug Administration or by any other regulatory authority, and it is not commercially available in any market. OpenBiome is acting only in the capacity of distributor of investigational FMT preparations manufactured by the University of Minnesota under an FDA-reviewed investigational new drug application (IND).

Before placing an order for any investigational FMT from OpenBiome/UMN, a licensed physician must submit a registration form, agree to comply with applicable regulatory requirements intended to safeguard the patients under their care, and be added as an investigator to the research IND that authorizes expanded access to the investigational biologic for appropriate patients.

©OpenBiome 2022, 501(c)(3) not-for-profit organization

Scroll To Top